Pegylated liposomal doxorubicin
Pegylated liposomal doxorubicin is a type of drug delivery system. It consists of the chemotherapeutic agent doxorubicin encapsulated within a liposomal formulation that has been modified with polyethylene glycol (PEG) to prolong its circulation time in the body.
Lab products found in correlation
5 protocols using pegylated liposomal doxorubicin
Solubilization and Preparation of Experimental Compounds
Formulation and Preparation of Anticancer Drugs
Exosome Purification and Characterization
Combination Therapy Dosage Protocols
Liposomal Drug Delivery Formulations
were used: hydrogenated soybean phosphatidylcholine (HSPC) (Lipoid,
Germany), methoxypolyethylene glycol distearoyl phosphatidylethanolamine
(mPEG2000-DSPE) (Biolab, Jerusalem, Israel), cholesterol (Chol) (Sigma,
St. Louis, MO), alendronic acid (Teva, Israel, and Tokyo Chemical
Industry Co Ltd., Japan), doxorubicin (Teva, Israel), PEGylated liposomal
doxorubicin (Janssen Pharmaceuticals, NJ, USA, commercial name Doxil
or Caelyx), mitomycin C prodrug (MLP) conjugate: 2,3-(distearoyloxy)propane-1-dithio-4′-benzyloxycarbonyl-MMC
(Aptuit-Laurus, Hyderabad, India).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!